Clinical trialPhase 1 / Phase 2Terminated
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
A phase1b/2 Clinical Trial of Chemotherapy and the AXL-inhibitor Bemcentinib for Patients With Metastatic Pancreatic Cancer
- Outcome
- Stopped earlyFunding was terminated early because research interests were going in a different direction. (Business decision)
- Phase
- Phase 1 / Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 3 January 2019
- Expected end
- 27 June 2022
- Enrollment
- 9 participants
- Sites
- 1
- Primary outcomes
- Overall Response Rate (ORR)
- Sponsor
- Other
- Results posted
- 2023-11-09
- Last update
- 9 November 2023
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Determine the overall response rate (ORR) of bemcentinib plus chemotherapy (nab-paclitaxel/gemcitabine) in patients with metastatic pancreatic adenocarcinoma.
Detailed description public domain (ClinicalTrials.gov)
Bemcentinib inhibits pancreatic cancer proliferation as monotherapy and in combination with gemcitabine through inhibition of the Axl pathway. The combination of nab-paclitaxel/gemcitabine has encouraging signs of clinical activity in patients with metastatic pancreatic cancer38. We would like to build on this combination in a biomarker driven phase 1b/2 clinical trial of bemcentinib in nab-paclitaxel/gemcitabine for patients with metastatic pancreatic cancer.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Overall Response Rate (ORR) [Every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.]. Count Of Participants, Participants. Phase 1b (n=7): 2; Phase 2 (n=0): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Complete Response Rate (CR) [Every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.]. Count Of Participants, Participants. Phase 1b (n=7): 0; Phase 2 (n=0): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Clinical Benefit Rate [Every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.]. Count Of Participants, Participants. Phase 1b (n=7): 6; Phase 2 (n=0): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With an Adverse Event of Grade 3 or Higher [Every 4 months from time of first dose of study drug until completion of treatment for approximately 42 months.]. Count Of Participants, Participants. Phase 1b (n=9): 5; Phase 2 (n=0): 0.